


Palonosetron-d3 hydrochloride

Cat. No.:	HY-A0021S
CAS No.:	1246816-81-8
Molecular Formula:	C ₁₉ H ₂₂ D ₃ ClN ₂ O
Molecular Weight:	335.89
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Palonosetron-d3 hydrochloride is the deuterium labeled Palonosetron hydrochloride. Palonosetron hydrochloride is a 5-HT ₃ antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) ^{[1][2]} .
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Vishnu Murthy M, Srinivas K, Kumar R, Mukkanti K. Development and validation of a stability-indicating LC method for determining palonosetron hydrochloride, its related compounds and degradation products using naphthaethyl stationary phase. *J Pharm Biomed Anal*. 2011 Sep 10;56(2):429-35.
- [3]. Ajioka H, Morita F, Akizawa Y, Yoshida K, Kitamura R, Takimoto H. Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI 1.V. Injection 0.75 mg), a novel antiemetic 5-HT₃-receptor antagonist. *Nihon Yakurigaku Zasshi*. 2010 Aug;136(2):113-20.
- [4]. Ruhlmann C, Herrstedt J. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. *Expert Rev Anticancer Ther*. 2010 Feb;10(2):137-48.
- [5]. Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration. *Am J Health Syst Pharm*. 2007 Jun 1;64(11):1209-13.
- [6]. Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglén, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al. 2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT₃ receptor antagonists. *J. Med. Chem.*, 1993, 36 (18), pp 2645-2657

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA